{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:39Z","timestamp":1762004739321},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,22]],"date-time":"2015-08-22T00:00:00Z","timestamp":1440201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.nefro.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T16:31:58Z","timestamp":1442334718000},"page":"578-581","source":"Crossref","is-referenced-by-count":2,"title":["Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype\u2013phenotype expression"],"prefix":"10.1016","volume":"35","author":[{"given":"Christos","family":"Paliouras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Aperis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Lamprianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgos","family":"Ntetskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Roufas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polichronis","family":"Alivanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2015.08.001_bib0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nefro.2015.08.001_bib0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gene.2013.11.073","article-title":"Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy","volume":"536","author":"Quinta","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.nefro.2015.08.001_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"Van der Tol","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.nefro.2015.08.001_bib0145","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study of on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nefro.2015.08.001_bib0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.nefro.2015.08.001_bib0155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2015.08.001_bib0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2015.08.001_bib0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nefro.2015.08.001_bib0170","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2015.08.001_bib0175","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.08.001_bib0180","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nefro.2015.08.001_bib0185","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease. A randomized controlled trial","volume":"285","author":"Sciffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.nefro.2015.08.001_bib0190","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.08.001_bib0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Sciffmann","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nefro.2015.08.001_bib0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilkox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2015.08.001_bib0205","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nefro.2015.08.001_bib0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefro.2015.08.001_bib0215","first-page":"1186","article-title":"Nature and frequency of mutations in the \u03b1-galactosidase A gene that cause Fabry disease","volume":"S3","author":"Eng","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2015.08.001_bib0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nefro.2015.08.001_bib0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1016\/j.nefro.2015.08.001_bib0230","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions","volume":"7","author":"Alfadhel","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nefro.2015.08.001_bib0235","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5414\/CNP69445","article-title":"Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy","volume":"69","author":"Torra","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefro.2015.08.001_bib0240","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2015.08.001_bib0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nefro.2015.08.001_bib0250","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS ONE"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699515001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T06:53:37Z","timestamp":1537340017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699515001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0211699515001332"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2015.08.001","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}